CN108125914A - A kind of olmesartan medoxomil hydrochlorothiazide Compound preparation - Google Patents
A kind of olmesartan medoxomil hydrochlorothiazide Compound preparation Download PDFInfo
- Publication number
- CN108125914A CN108125914A CN201611089812.3A CN201611089812A CN108125914A CN 108125914 A CN108125914 A CN 108125914A CN 201611089812 A CN201611089812 A CN 201611089812A CN 108125914 A CN108125914 A CN 108125914A
- Authority
- CN
- China
- Prior art keywords
- olmesartan medoxomil
- compound preparation
- content
- taurine
- hydrochlorothiazide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
Abstract
The present invention provides a kind of olmesartan medoxomil hydrochlorothiazide Compound preparation, which is included the olmesartan medoxomil, Hydrochioro, taurine of micronizing, prepared using wet granulation technique.The compound preparation solubility is high, dissolution rate is fast, bioavilability is high, stability is good；Simple for process, cost savings are suitble to commercially produce.
Description
Technical field
The invention belongs to pharmaceutical technology fields, are specifically related to a kind of olmesartan medoxomil hydrochlorothiazide Compound preparation, with
And the preparation method of the compound preparation.
Background technology
Olmesartan medoxomil is a kind of selective angiotensin II receptor antagonist, is drawn in the market in anti-hypertension
Extensive concern is played.The medicine is blocked by the combination of selective exclusion Angiotensin II and vascular smooth muscle AT1 receptors
The vasoconstriction effect of Angiotensin II, adverse reaction is smaller, and patient's tolerance is good, the curative effect in Mild or moderate hypertension treatment
Well.Its compound structure is as follows：
Hydrochioro be it is a kind of be suitable for it is light, moderate hypertension, be especially suitable for older patients with isolated systolic hypertension and mental and physical efforts
The thiazide diuretic of the treatment of failure accompanied with hypertension, its chemical name is chloro- 3, the 4- dihydros -2H-1 of 6-, 2,4- benzo thiophenes
Diazine -7- sulfonamide -1,1- dioxide has following structural formula：
Olmesartan medoxomil and Hydrochioro combination use and more excellent effect are shown than each single dose, in hypertension is treated
Show good synergistic therapeutic action.
Entitled 2,3- dihydroxy -2- cyclobutenyls -4- (1- hydroxyl -1- the Methylethyls) -2- of chemistry of olmesartan medoxomil
Butyl -1- [4- (2-1H- tetrazolium -5- phenyl) benzyl] imidazoles -5- carboxylate ring -2,3- carbonic esters, belong to fat-soluble
Compound, it is not soluble in water, when administered orally, due to olmesartan medoxomil property not soluble in water, its in existing preparation is caused to exist
It is not easy to soak and spread in water, i.e., the tablet prepared using conventional preparation technique is easy to crystallization or Precipitation in gastro-intestinal Fluid
And cannot dissolve out, bioavilability about 26%, it greatly affected the absorption and utilization of drug.
In addition Hydrochioro has certain hydrophobicity, combines when it with olmesartan medoxomil and be made as insoluble drug
During tablet, due to its hydrophobic effect meeting further such that olmesartan medoxomil dissolution slows down.
CN200880017194.9 disclose olmesartan medoxomil crushing crystallize with and preparation method thereof, tied using the crushing
Crystalline substance prepares drug and is dissolved out convenient for control.But the present inventor is found that while the Olmesartan using micronizing during the experiment
Ester, which prepares olmesartan medoxomil hydrochlorothiazide Compound preparation, can improve the rate of dissolution of drug, but the olmesartan medoxomil being micronized
Crystal form disorder easily occurs due to being pressurized or rubbing during tabletting, causes preparing, under storing process and hot environment
The decomposition of active material causes the reduction of medicament contg and impurity content raising.
Therefore, it is badly in need of the olmesartan medoxomil Hydrochioro that a kind of dissolution rate is fast, bioavilability is high, stability is good at present
Compound preparation.
Invention content
The present invention provides the olmesartan medoxomil Hydrochioros that a kind of dissolution rate is fast, bioavilability is high, stability is good
Compound preparation, and preparation method thereof.
Present invention firstly provides a kind of olmesartan medoxomil hydrochlorothiazide Compound preparation, which includes micronizing
Olmesartan medoxomil, Hydrochioro, stabilizer and other pharmaceutically acceptable auxiliary materials；Wherein, the olmesartan medoxomil of micronizing
Grain size d0.9 be less than 75 μm；Stabilizer is taurine.
Aforementioned stable agent further includes PLURONICS F87；Wherein, the weight ratio of taurine and PLURONICS F87 is preferably 1:
0.5-2, most preferably 1:1.
Calculated in weight percent, the content of aforementioned stable agent is 0.5%-10%.
Other above-mentioned pharmaceutically acceptable auxiliary materials, including but not limited to filler, adhesive, disintegrant, lubricant, profit
One or more of humectant, corrigent.
It is calculated in weight percent, the Olmesartan ester content of micronizing is 5%-20%, Hydrochioro content be 1%-15%,
Filling agent content is 10%-90%, binder content 0%-20%, disintegrant content 0%-20%, lubricant content 0%-5%.
Above-mentioned filler includes but not limited in microcrystalline cellulose, mannitol, lactose, starch, sucrose, dextrin, glucose
One or more.Adhesive include but not limited to hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinylpyrrolidone,
One or more of povidone, starch slurry.Disintegrant includes but not limited to low-substituted hydroxypropyl cellulose, carboxymethyl cellulose
One or more of element, crospovidone, sodium carboxymethyl starch, croscarmellose sodium.Lubricant includes but unlimited
In one or more of magnesium stearate, stearic acid, talcum powder, superfine silica gel powder, lauryl sodium sulfate, fumaric acid sodium.Wetting
Agent is one kind in the aqueous solution of alcohol, water.
Corrigent includes but not limited to sugar, saccharin sodium, calcium benzosulphimide, honey element, steviol glycoside, glycyrrhizin, hexamethylene alkylamino
Sulfonic acid, cyclohexane sulfamic acid sodium, asparagine, dihydrochalcone, alcohol sugar, radix asparagi sweet extract, Sucralose, acesulfame-K, A Si
The sweeteners such as Ba Tian；One or more of aromatic such as fragrant citrus essence, strawberry essence.
Preferred filler is lactose and microcrystalline cellulose, and adhesive is hydroxypropyl cellulose, and disintegrant is low substitution hydroxyl
Propyl cellulose, lubricant are magnesium stearate.
The present inventor is studied by test of many times, finds to add in taurine or taurine and poloxamer in formula
188 composition can make olmesartan medoxomil hydrochlorothiazide Compound preparation during preparation and storage as stabilizer
Active constituent is not easily decomposed, and impurity content reduces；The composition ratio list using taurine and PLURONICS F87 is found by experiment
It is solely more preferable as the effect that stabilizer inhibits olmesartan medoxomil to decompose using taurine.In addition taurine and PLURONICS F87 be all
It with good water solubility, is mixed in process of production with olmesartan medoxomil, increases the hydrophily of olmesartan medoxomil, promoted
The dissolving of olmesartan medoxomil ensures the good dissolution rate of olmesartan medoxomil hydrochlorothiazide tablets and dissolution rate.
The present invention also provides the preparation methods of above-mentioned olmesartan medoxomil hydrochlorothiazide tablets, include the following steps：
A. it by the olmesartan medoxomil of micronizing, the pharmaceutically acceptable abundant mixing of other auxiliary materials of Hydrochioro and part, is made
Mixed powder；
B. it by the alcohol solution of taurine or aqueous solution, adds in above-mentioned mixed powder, wet granular processed；
C. it dries, whole grain；
D. other remaining pharmaceutically acceptable auxiliary materials and step c pellet through sieves, mixing and tabletting are taken.
The method b step can also be by the alcohol solution or aqueous solution of taurine and PLURONICS F87, add in above-mentioned
In mixed powder, wet granular processed.
Olmesartan medoxomil hydrochlorothiazide Compound preparation provided by the invention is using the olmesartan medoxomil of micronizing as activity
Ingredient increases the surface area of slightly solubility active constituent, and drug is made to have good dissolution rate and dissolution rate；Stabilizer is added in change
The olmesartan medoxomil of kind micronizing labile phenomenon of active constituent in preparation and storage, reduces impurity of the drug, makes obtained
Drug is with good stability；Taurine and PLURONICS F87 all have good water solubility, in process of production same Aomei
Husky smooth ester is mixed, and increases the hydrophily of olmesartan medoxomil, promotes the dissolving of olmesartan medoxomil, ensures olmesartan medoxomil hydrogen chlorine
The good dissolution rate of thiazine compound preparation and dissolution rate；Olmesartan medoxomil esodrix is prepared using conventional wet granulation technology
Piperazine compound preparation, simple for process, cost savings are more suitable for commercially producing.
Specific embodiment
Embodiment 1
Olmesartan medoxomil is micronized
It is 0.2-0.4Mpa that airslide disintegrating mill is set, which to crush compressed air pressure, and feeding compressed air pressure is 0.4-0.8Mpa.
Olmesartan medoxomil is subjected to ultramicro grinding by airslide disintegrating mill, obtains micronizing olmesartan medoxomil.
Embodiment 2
Prepare olmesartan medoxomil hydrochlorothiazide tablets
D0.9=10 μm of olmesartan medoxomil
Preparation process includes the following steps：
A. by the olmesartan medoxomil of micronizing, Hydrochioro, lactose, microcrystalline cellulose, hydroxypropyl cellulose, low substituted hydroxy-propyl
Mixed powder is made in the abundant mixing of cellulose；
B. it by taurine and the aqueous solution of PLURONICS F87, adds in above-mentioned mixed powder, wet granular processed；
C. it dries, arranges；
D. magnesium stearate and step c pellet through sieves, mixing and tabletting are taken.
Embodiment 3
Prepare olmesartan medoxomil hydrochlorothiazide tablets
D0.9=20 μm of olmesartan medoxomil
Preparation method is the same as embodiment 2
Embodiment 4
Prepare olmesartan medoxomil hydrochlorothiazide tablets
D0.9=50 μm of olmesartan medoxomil
Preparation method is the same as embodiment 2
Embodiment 5
Prepare olmesartan medoxomil hydrochlorothiazide tablets
D0.9=70 μm of olmesartan medoxomil
Preparation method is the same as embodiment 2
Embodiment 6
Prepare olmesartan medoxomil hydrochlorothiazide tablets
D0.9=5 μm of olmesartan medoxomil
Preparation method is the same as embodiment 2
Embodiment 7
Prepare olmesartan medoxomil hydrochlorothiazide tablets
D0.9=10 μm of olmesartan medoxomil
Preparation method is the same as embodiment 2
Embodiment 8
Prepare olmesartan medoxomil hydrochlorothiazide tablets
D0.9=10 μm of olmesartan medoxomil
Preparation method is the same as embodiment 2
Dissolution determination
According to dissolution determination method (2015 editions the 4th 0,931 second methods of general rule of Chinese Pharmacopoeia), using added with 0.35%
Polysorbas20 900ml pH6.5 phosphate buffers as dissolution medium, rotating speed 75rpm, to the place of embodiment 2-8
Fang Jinhang dissolution rates (%) measure.Acquired results are shown in Table 1.
Table 1
By above-mentioned data it is found that the olmesartan medoxomil Aquazide H prepared using the method for the present invention, was dissolved out in 30 minutes
Stabilization is basically reached, and final dissolution rate can reach more than 97%.
Detection of Stability
By the slice, thin piece of embodiment 2-8 simultaneously at 40 ± 2 DEG C, continuously placed 6 months in the environment of RH75% ± 5%, using efficient liquid
Phase method detects 0 day, the olmesartan medoxomil total impurities content of 6 months（%）, acquired results are shown in Table 2.
Table 2
From the data of table 2 it is known that after adding in stabilizer taurine or the composition of taurine and PLURONICS F87, piece
The content of total impurities is significantly inhibited in agent.Using the mixture of taurine and PLURONICS F87 as the effect of stabilizer
More preferably.
Embodiment 7
The selection of 7.1 stabilizers
Other auxiliary materials and dosage are with embodiment 2 in formula, and preparation method is the same as embodiment 2.
Dissolution determination
According to dissolution determination method (2015 editions the 4th 0,931 second methods of general rule of Chinese Pharmacopoeia), using added with 0.35%
Polysorbas20 900ml pH6.5 phosphate buffers as dissolution medium, rotating speed 75rpm, to above 7 prescriptions into
Row dissolution rate（%）It measures, dissolves out data comparison with embodiment 2, acquired results are shown in Table 3.
Table 3
By the data of table 1 and table 3 it is found that in terms of the selection of stabilizer, taurine or taurine and PLURONICS F87 are used
Composition there is higher solubility as olmesartan medoxomil Aquazide H made from stabilizer, result of extraction is more preferable.
Detection of Stability
By the slice, thin piece for being formulated 1-7 simultaneously at 40 ± 2 DEG C, continuously placed 6 months in the environment of RH75% ± 5%, using efficient liquid phase
Method detects 0 day, the husky smooth ester total impurities content of the Aomei of 6 months（%）, 0 day, the olmesartan medoxomil of 6 months with embodiment 2
Total impurities content data compares, and acquired results are shown in Table 4.
Table 4
By the data of table 4 it is found that the olmesartan medoxomil being micronized in the case where being added without stabilizer is in the mistake for preparing and storing
It is extremely unstable in journey, it is easy to be decomposed into other impurities；The stability of olmesartan medoxomil makes moderate progress after addition stabilizer, especially
It is to add in taurine or the composition effect of taurine and PLURONICS F87 to become apparent, wherein taurine and PLURONICS F87
Composition it is best as stabilizer effect.
Embodiment 8
The selection of 8.1 taurines and poloxamer proportioning
Other auxiliary materials and dosage are with embodiment 2 in comparative example, and preparation method is the same as embodiment 2
8.2 dissolution determination
According to dissolution determination method (2015 editions the 4th 0,931 second methods of general rule of Chinese Pharmacopoeia), using added with 0.35%
The pH6.5 phosphate buffers of the 900ml of polysorbas20 carry out above 2 prescriptions as dissolution medium, rotating speed 75rpm
Dissolution rate（%）It measures, is compared with 2 dissolution data of embodiment, acquired results are shown in Table 5.
Table 5
8.3 Detection of Stability
By the slice, thin piece of comparative example 1-2 simultaneously at 40 ± 2 DEG C, continuously placed 6 months in the environment of RH75% ± 5%, using efficient liquid
Phase method detects 0 day, the olmesartan medoxomil total impurities content of 6 months（%）, 0 day with embodiment 2, the olmesartan medoxomil of 6 months it is total
Impurity content data comparison, acquired results are shown in Table 6.
Table 6
By table 5 with the data in table 6 it is found that when the ratio difference that taurine and PLURONICS F87 use, for Olmesartan
The influence of ester Aquazide H dissolution is little；But when the mass ratio of the two dosage is 1:When 1, the stability of olmesartan medoxomil
It is highest.
Claims (10)
1. a kind of olmesartan medoxomil hydrochlorothiazide Compound preparation, which is characterized in that the compound preparation includes the Aomei of micronizing
Husky smooth ester, Hydrochioro, stabilizer and other pharmaceutically acceptable auxiliary materials；Wherein, stabilizer is taurine, micronizing
The grain size d0.9 of olmesartan medoxomil is less than 75 μm.
2. olmesartan medoxomil hydrochlorothiazide Compound preparation according to claim 1, which is characterized in that the stabilizer also contains
There is PLURONICS F87.
3. olmesartan medoxomil hydrochlorothiazide Compound preparation according to claim 2, which is characterized in that the taurine and pool
The weight ratio of Luo Shamu 188 is 1:0.5-2.
4. olmesartan medoxomil hydrochlorothiazide Compound preparation according to claim 3, which is characterized in that the taurine and pool
The weight ratio of Luo Shamu 188 is 1:1.
5. olmesartan medoxomil hydrochlorothiazide Compound preparation according to claim 1 or 2, which is characterized in that with weight percent
Than calculating, the content of the stabilizer is 0.5%-10%.
6. olmesartan medoxomil hydrochlorothiazide Compound preparation according to claim 1 or 2, which is characterized in that it is described pharmaceutically
Other acceptable auxiliary materials are one or more of filler, adhesive, disintegrant, lubricant, wetting agent, corrigent.
7. olmesartan medoxomil hydrochlorothiazide Compound preparation according to claim 6, which is characterized in that the filler is
One or more of microcrystalline cellulose, mannitol, lactose, starch, sucrose, dextrin, glucose；The adhesive is hydroxypropyl
One or more of base cellulose, hydroxypropyl methyl cellulose, polyvinylpyrrolidone, povidone, starch slurry；Described collapses
Solution agent is low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, crospovidone, sodium carboxymethyl starch, cross-linked carboxymethyl fiber
One or more of plain sodium；The lubricant is magnesium stearate, stearic acid, talcum powder, superfine silica gel powder, dodecyl sulphate
One or more of sodium, fumaric acid sodium；The wetting agent is one kind in the aqueous solution of alcohol, water.
8. olmesartan medoxomil hydrochlorothiazide Compound preparation according to claim 6, which is characterized in that by weight percentage
It calculates, the content of the olmesartan medoxomil of micronizing is 5%-20%, the content of Hydrochioro is 1%-15%, the content of filler is 10%-
90%th, the content of adhesive is 0%-20%, the content of disintegrant is 0%-20%, the content of lubricant is 0%-5%.
A kind of 9. method for preparing olmesartan medoxomil hydrochlorothiazide Compound preparation described in claim 1, which is characterized in that including
Following steps：
A. it by the olmesartan medoxomil of micronizing, the pharmaceutically acceptable abundant mixing of other auxiliary materials of Hydrochioro and part, is made
Mixed powder；
B. it by the alcohol solution of taurine or aqueous solution, adds in above-mentioned mixed powder, wet granular processed；
C. it dries, whole grain；
D. other remaining pharmaceutically acceptable auxiliary materials and step c pellet through sieves, mixing and tabletting are taken.
A kind of 10. method of olmesartan medoxomil hydrochlorothiazide Compound preparation prepared described in claim 2, which is characterized in that packet
Include following steps：
A. it by the olmesartan medoxomil of micronizing, the pharmaceutically acceptable abundant mixing of other auxiliary materials of Hydrochioro and part, is made
Mixed powder；
B. it by taurine and the alcohol solution or aqueous solution of PLURONICS F87, adds in above-mentioned mixed powder, wet granular processed；
C. it dries, whole grain；
D. other remaining pharmaceutically acceptable auxiliary materials and step c pellet through sieves, mixing and tabletting are taken.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611089812.3A CN108125914B (en) | 2016-12-01 | 2016-12-01 | Olmesartan medoxomil and hydrochlorothiazide compound preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611089812.3A CN108125914B (en) | 2016-12-01 | 2016-12-01 | Olmesartan medoxomil and hydrochlorothiazide compound preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108125914A true CN108125914A (en) | 2018-06-08 |
| CN108125914B CN108125914B (en) | 2021-02-19 |
Family
ID=62387584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611089812.3A Active CN108125914B (en) | 2016-12-01 | 2016-12-01 | Olmesartan medoxomil and hydrochlorothiazide compound preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108125914B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111557924A (en) * | 2020-05-13 | 2020-08-21 | 重庆赛凌医药有限公司 | Preparation method of olmesartan medoxomil hydrochlorothiazide tablet and olmesartan medoxomil hydrochlorothiazide tablet |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102655856A (en) * | 2009-06-19 | 2012-09-05 | 成药技术Ip控股（泽西）有限公司 | Nanoparticulate olmesartan medoxomil compositions, process for the preparation thereof and pharmaceutical compositions containing them |
-
2016
- 2016-12-01 CN CN201611089812.3A patent/CN108125914B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102655856A (en) * | 2009-06-19 | 2012-09-05 | 成药技术Ip控股（泽西）有限公司 | Nanoparticulate olmesartan medoxomil compositions, process for the preparation thereof and pharmaceutical compositions containing them |
Non-Patent Citations (4)
| Title |
|---|
| 刘程等主编: "《表面活性剂性质理论与应用》", 30 June 2003, 北京工业大学出版社 * |
| 刘耕陶主编: "《当代药理学》", 31 May 2008, 中国协和医科大学出版社 * |
| 方亮主编: "《药剂学》", 31 March 2016, 中国医药科技出版社 * |
| 朱鼎良等: "奥美沙坦酯/氢氯噻嗪复方片剂用于奥美沙坦酯单药治疗血压未达标的原发性轻中度高血压患者的临床研究", 《中华高血压杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111557924A (en) * | 2020-05-13 | 2020-08-21 | 重庆赛凌医药有限公司 | Preparation method of olmesartan medoxomil hydrochlorothiazide tablet and olmesartan medoxomil hydrochlorothiazide tablet |
| CN111557924B (en) * | 2020-05-13 | 2022-05-10 | 重庆赛凌医药有限公司 | Preparation method of olmesartan medoxomil hydrochlorothiazide tablet and olmesartan medoxomil hydrochlorothiazide tablet |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108125914B (en) | 2021-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2116242B1 (en) | New pharmaceutical composition | |
| PL226401B1 (en) | Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient | |
| CN101516344A (en) | Pharmaceutical compositions comprising nilotinib or its salt | |
| CN102292085A (en) | Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same | |
| CN103608342A (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
| WO2011002857A2 (en) | 3-cyanoquinoline tablet formulations and uses thereof | |
| KR100908418B1 (en) | Quinolinone derivative pharmaceutical composition and preparation method thereof | |
| CN107913256A (en) | A kind of macitentan oral disnitegration tablet for treating pulmonary hypertension and preparation method thereof | |
| US20120010216A1 (en) | Pharmaceutical compositions containing vanoxerine | |
| US20200323838A1 (en) | Lenalidomide immediate release formulations | |
| CN101715448B (en) | Therapeutic uses of imidazol-5-carboxylic acid derivatives | |
| CN108125914A (en) | A kind of olmesartan medoxomil hydrochlorothiazide Compound preparation | |
| CN102836161A (en) | Medicament compound preparation formed by mixing olmesartan medoxomil with benzene sulfonic acid amlodipine and hydrochlorothiazide | |
| CN102088972A (en) | Pharmaceutical compositions containing imidazole-5-carboxylic acid derivatives and preparation method and use thereof | |
| EP3236950B1 (en) | Pharmaceutical composition comprising candesartan or pharmaceutically acceptable salts or esters thereof and amlodipine or pharmaceutically acceptable salts thereof | |
| CN101890012B (en) | Paracetamol,loratadine and pseudoephedrine sulfate sustained release tablet and preparation method thereof | |
| CN101095671B (en) | Iguratimod oral double-layer sustained-release preparation | |
| EP1328274A1 (en) | Compositions containing an inhibitor of dihydrofolate reductase and a folate | |
| WO2009070973A1 (en) | Therapeutic composition containing amlodipine nicotinate and sartans | |
| EP2571484A2 (en) | Effervescent formulations | |
| US20100008956A1 (en) | Composition and combinations of carboxylic acid losartan in dosage forms | |
| CN102327220B (en) | Solid loratadine lipidosome preparation | |
| CN103751134A (en) | Risperidone orally-disintegrating tablet | |
| CN103156816A (en) | Almotriptan drug absorbed through mouth mucosa | |
| CN100496498C (en) | Medicinal composition containing enalapril or genazepril and sotalol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 101113 Beijing Guangyuan Tongzhou District Industrial Development Zone in Tongzhou Street No. 8 Applicant after: Beijing Fuyuan Pharmaceutical Co., Ltd. Address before: 101113 Beijing Guangyuan Tongzhou District Industrial Development Zone in Tongzhou Street No. 8 Applicant before: Beijing Winsunny Pharmaceutical Co., Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |